1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This program supports clinical centers to participate in research on optimal treatment strategies for anti-obesity medications in children and adolescents. It is a clinical trial required opportunity.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the opportunity page linked on this listing to help you evaluate fit faster.
Optimal Treatment Strategies for use of Anti-Obesity Medications in Children and Adolescents - NIDDK Advisory & Coordinating Committees National Diabetes & Digestive & Kidney Diseases Advisory Council Optimal Treatment Strategies for use of Anti-Obesity Medications in Children and Adolescents Return to Concept Clearances Optimal Treatment Strategies for use of Anti-Obesity Medications in Children and Adolescents Stavroula Osganian, M.
D. , Sc. D.
, M. P. H.
Obesity in youth remains prevalent and a major public health problem. Since 2020, three anti-obesity medications have been approved by the FDA in youth ages 12 years and older with non-syndromic obesity. Studies of AOMs demonstrate significant improvements in BMI and cardiometabolic risk factors.
However, a strong evidence base is lacking to guide treatment decisions for youth, in which physical and psychosocial growth and development need to be considered, including optimal developmental stage for AOM initiation; drug class and dosage; behavioral, nutritional and physical activity interventions to support growth and development and preservation of lean body mass; type and intensity of lifestyle interventions needed to support optimal weight and psychosocial outcomes; and potential strategies to enable discontinuation of AOMs and avoid lifetime use while preserving health benefits.
This initiative will support investigator-initiated research to test AOM treatment strategies for youth with obesity that could be implemented in clinical care settings to maximize benefits and minimize risks of AOM use.
Given the rapidly changing landscape and knowledge gaps in treatment strategies and safety with AOM use, well-designed studies are needed to support the appropriate, effective, and safe use of AOMs in diverse populations of children and adolescents. Findings will inform optimal medical management of children and adolescents with obesity.
According to the current listing, eligibility includes: Varies, typically includes academic institutions, research organizations. Specific eligibility will be detailed in the official RFA. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,000,000 per award (3 awards, $3,000,000 pool). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was October 9, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required) is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This notice of funding opportunity (NOFO) invites applications designed to examine the efficacy and clinical effectiveness of multimodality digital health technology approaches to the remote management of diabetes.
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trial Required) (RFA-DK-26-315) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This Notice of Funding Opportunity (NOFO) invites applications for innovative research on the use of digital health technologies (DHT) for the management of type 2 diabetes.